Editor
Jeremy Grushcow is a partner at Norton Rose OR LLP. Jeremy has a Ph.D. in Molecular Genetics and Cell Biology, and is a member of the Bar in Ontario, New York and Illinois. His practice focuses on life science and technology companies. He has represented private equity firms, investment banks, operating companies and founders in connection with public and private offerings, mergers and acquisitions, joint ventures and other strategic transactions, licensing and outsourcing agreements, operating and service agreements and ongoing disclosure advice. Prior to joining Norton Rose, Jeremy practised in the area of intellectual property transactions at Kirkland & Ellis LLP and in capital markets at Shearman & Sterling LLP. LinkedIn Profile; Norton Rose Bio. Send email. Posts by Jeremy.
Contributors
Jacob Cawker is an associate at Norton Rose, and is part of our Life Sciences transactional team. He has an Honours Bachelor of Science from the University of Toronto at Mississauga with a specialist in Psychology and a particular interest in neuroscience, and he worked in a behaviour genetics lab at the University of Toronto before entering law school at Osgoode Hall University. Send email. Posts by Jacob.
Mark Curtis is an associate at the Vanscia Group, a consulting firm focused on the commercialization of university-stage life science innovations in North America and abroad. He has frequently worked as a consultant to Bloom Burton & Co., a boutique investment bank in Toronto that focuses exclusively on the biotechnology and healthcare industries. Prior to this he was involved in stem cell research at the Ontario Cancer Institute. Mark completed a Bachelor of Science degree in biology at Queen’s University and a Master’s degree in biotechnology, with a specialization in stem cell biology, at the University of New South Wales in Sydney, Australia. Send email. Posts by Mark.
Dani Peters is a Canadian who works for a Washington, D.C. government affairs firm but is based in Toronto. She is specialized in helping life science and environment technology companies access the U.S. government for funding, but is also involved in a variety of healthcare-related legislation, including patent reform and follow-on biologics. Dani’s firm, Fabiani & Company assists its clients in obtaining U.S. government funding/ contracts in defence/intelligence, homeland security, environment technology and biotechnology. The company also represents clients before the U.S. Congress and Executive Branch on a wide variety of policy areas. Send email. Posts by Dani.
Beni Rovinski is a Managing Director at Lumira Capital. Beni’s investment focus has primarily been on Canadian and US mid- to late-stage private and public companies involved in drug discovery and development, biological and small molecule therapeutics, drug delivery, specialty pharmaceuticals, genomics, proteomics and diagnostic devices. Lumira Bio. Posts by Beni.
Wayne Scharr is a semi-retired healthcare consultant with over thirty years of experience in the biopharmaceutical and financial sectors. He initially worked in the old biotechnology industry isolating biologicals from animal tissues and human blood. After a stint as a lobbyist for the Canadian generic drug industry, he moved to the financial sector in 1992. He has been an analyst for four independent investment banks, interspersed between time with biotechnology companies, venture capital and investor relations. He has a Ph.D in Chemistry from Queen’s University (Kingston) and an MBA from York University (Toronto). Send email. Posts by Wayne.
Peter van der Velden is the President and CEO of Lumira Capital. Lumira Bio. Posts by Peter.
Editor and Contributor
Audrey Fried-Grushcow is the blog’s editor as well as an occasional contributor focusing on case law of interest to the cross-border biotech community. Audrey is a U.S.-trained lawyer and mediator. After law school, Audrey clerked for Judge William J. Bauer on the Seventh Circuit Court of Appeals and practiced in the area of complex commercial litigation for several years at Mayer Brown LLP before turning her attention to conflict resolution and social media. Send email. Posts by Audrey.
Past Contributors
Richard Chan was a science consultant at R&D Funding Management. He now works at Deloitte. His interests lie in promoting the life science and biotech industries in Canada. Richard has a Ph.D. specializing in molecular biology and biotechnology. More recently, he was a postdoctoral research fellow working on cancer signaling and proteomics projects at both Beth Israel Deaconess Medical Center/Harvard Medical School in Boston and at the Ontario Cancer Institute in Toronto. LinkedIn Profile. Email Richard. Posts by Richard.
